Integrated Financial Statements From 2010 to 2021

Integrated Biopharma financial statements provide useful quarterly and yearly information to potential Integrated Biopharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Integrated Biopharma financial statements helps investors assess Integrated Biopharma's valuation, profitability, and current liquidity needs.
There are currently eighty-one fundamental trends for Integrated Biopharma that can be evaluated and compared over time across competitors. Make sure you confirm Integrated Biopharma's regular fundamentals against the trend between 2010 and 2021 to make sure the company can sustain itself down the road.
Integrated Biopharma Working Capital is very stable at the moment as compared to the past year. Integrated Biopharma reported last year Working Capital of 8.76 Million.

Integrated Financial Statements 

 
Refresh
Check Integrated Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Integrated main balance sheet or income statement drivers, such as Consolidated Income of 8.6 M, Cost of Revenue of 52.7 M or Earning Before Interest and Taxes EBIT of 8.1 M, as well as many exotic indicators such as Asset Turnover of 2.49, Book Value per Share of 0.52 or Current Ratio of 1.69. Integrated financial statements analysis is a perfect complement when working with Integrated Biopharma Valuation or Volatility modules. It can also supplement various Integrated Biopharma Technical models. Check out Risk vs Return Analysis.

Integrated Biopharma Revenues

61.3 MillionShare

Integrated Biopharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets23.6 M25.4 M16.1 M
Increasing
Slightly volatile
Cash and Equivalents268.7 K210 K205.5 K
Increasing
Slightly volatile
Investments448.3 K450.9 K492.4 K
Decreasing
Slightly volatile
Investments Current448.3 K450.9 K492.4 K
Decreasing
Slightly volatile
Property Plant and Equipment Net3.8 M4.1 M2.4 M
Increasing
Slightly volatile
Inventory11.1 M11.7 M7.8 M
Increasing
Slightly volatile
Tax Assets3.5 M3.3 M1.3 M
Increasing
Slightly volatile
Trade and Non Trade Receivables5.5 M5.8 M3.8 M
Increasing
Slightly volatile
Trade and Non Trade Payables3.7 M3.5 M4.6 M
Decreasing
Slightly volatile
Goodwill and Intangible Assets664.8 K668.7 K730.3 K
Decreasing
Slightly volatile
Total Liabilities13.7 M11.1 M19 M
Decreasing
Slightly volatile
Shareholders Equity15.5 M14.3 M(2.4 M)
Increasing
Slightly volatile
Current Assets17.3 M18 M12.4 M
Increasing
Slightly volatile
Assets Non Current6.3 M7.4 M3.7 M
Increasing
Slightly volatile
Current Liabilities10 M9.2 M11.9 M
Decreasing
Stable
Liabilities Non Current1.9 M1.9 M6.9 M
Decreasing
Slightly volatile
Total Debt8.5 MM12.9 M
Decreasing
Slightly volatile
Debt CurrentM4.1 MM
Increasing
Stable
Debt Non Current1.9 M1.9 M6.8 M
Decreasing
Slightly volatile
Shareholders Equity USD15.5 M14.3 M(2.4 M)
Increasing
Slightly volatile
Cash and Equivalents USD268.7 K210 K205.5 K
Increasing
Slightly volatile
Total Debt USD8.5 MM12.9 M
Decreasing
Slightly volatile

Integrated Biopharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues61.3 M63.6 M45.7 M
Increasing
Slightly volatile
Cost of Revenue52.7 M54.1 M39.8 M
Increasing
Slightly volatile
Selling General and Administrative ExpenseM3.7 M3.5 M
Increasing
Slightly volatile
Operating ExpensesM3.7 M3.5 M
Increasing
Slightly volatile
Interest Expense262.7 K256 K769.2 K
Decreasing
Slightly volatile
Income Tax Expense(786.2 K)(766 K)(123.4 K)
Decreasing
Slightly volatile
Consolidated Income8.6 MM2.5 M
Increasing
Slightly volatile
Net Income8.6 MM2.5 M
Increasing
Slightly volatile
Net Income Common Stock8.6 MM2.5 M
Increasing
Slightly volatile
Weighted Average Shares29.9 M29.7 M23.9 M
Increasing
Slightly volatile
Weighted Average Shares Diluted33.8 M32.1 M29.6 M
Increasing
Slightly volatile
Earning Before Interest and Taxes EBIT8.1 M7.5 M3.2 M
Increasing
Slightly volatile
Revenues USD61.3 M63.6 M45.7 M
Increasing
Slightly volatile
Net Income Common Stock USD8.6 MM2.5 M
Increasing
Slightly volatile
Earning Before Interest and Taxes USD8.1 M7.5 M3.2 M
Increasing
Slightly volatile
Gross Profit8.6 M9.5 M5.8 M
Increasing
Slightly volatile
Operating Income4.7 M5.8 M2.3 M
Increasing
Slightly volatile

Integrated Biopharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Business Acquisitions and Disposals81.4 K96 K55.2 K
Decreasing
Very volatile
Net Cash Flow from Financing(3.1 M)(3 M)(651.7 K)
Decreasing
Slightly volatile
Issuance Repayment of Debt Securities (3.1 M)(3.1 M)(702.9 K)
Decreasing
Slightly volatile
Issuance Purchase of Equity Shares20.4 K23 K9.9 K
Increasing
Slightly volatile
Net Cash Flow from Operations3.3 MM701.1 K
Increasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents(197.1 K)(192 K)(163.2 K)
Increasing
Slightly volatile
Share Based Compensation249.2 K231 K108.1 K
Increasing
Slightly volatile
Depreciation Amortization and Accretion754.7 K826 K520.3 K
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share0.290.270.0916
Increasing
Slightly volatile
Earnings per Diluted Share0.270.250.0815
Increasing
Slightly volatile
Earnings per Basic Share USD0.290.270.0916
Increasing
Slightly volatile
Return on Average Equity0.720.8090.2667
Increasing
Slightly volatile
Return on Average Assets0.260.3160.1231
Increasing
Slightly volatile
Return on Invested Capital0.310.3710.1767
Increasing
Slightly volatile
Gross Margin0.150.1490.1269
Increasing
Slightly volatile
Profit Margin0.130.1260.0468
Increasing
Slightly volatile
EBITDA Margin0.110.1310.0726
Increasing
Slightly volatile
Return on Sales0.09850.1180.0612
Increasing
Slightly volatile
Asset Turnover2.492.5062.8966
Decreasing
Slightly volatile
Enterprise Value over EBITDA5.064.9036.3169
Decreasing
Slightly volatile
Enterprise Value over EBIT5.515.07.2088
Decreasing
Slightly volatile
Price to Earnings Ratio4.054.0743.2581
Increasing
Slightly volatile
Sales per Share2.262.141.9238
Increasing
Slightly volatile
Price to Sales Ratio0.550.5140.1601
Increasing
Slightly volatile
Price to Book Value1.832.2850.5786
Increasing
Slightly volatile
Debt to Equity Ratio0.830.775(0.6179)
Increasing
Slightly volatile
Current Ratio1.691.9491.0724
Increasing
Slightly volatile
Free Cash Flow per Share0.10.0930.0135
Increasing
Slightly volatile
Book Value per Share0.520.483(0.1544)
Increasing
Slightly volatile
Tangible Assets Book Value per Share0.860.8570.6519
Increasing
Slightly volatile

Integrated Biopharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings before Tax7.8 M7.2 M2.4 M
Increasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization EBITDAM8.3 M3.7 M
Increasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization USDM8.3 M3.7 M
Increasing
Slightly volatile
Market Capitalization35.3 M32.7 M9.1 M
Increasing
Slightly volatile
Enterprise Value34.3 M40.8 M21.3 M
Increasing
Slightly volatile
Invested Capital21.9 M22 M16.6 M
Increasing
Slightly volatile
Average Equity10.7 M9.9 M(3.4 M)
Increasing
Slightly volatile
Average Assets24 M25.4 M16.8 M
Increasing
Slightly volatile
Invested Capital Average20.9 M20.2 M17 M
Increasing
Slightly volatile
Tangible Asset Value23.5 M25.4 M15.8 M
Increasing
Slightly volatile
Free Cash FlowM2.8 M443.8 K
Increasing
Slightly volatile
Working Capital9.5 M8.8 M692.4 K
Increasing
Slightly volatile

Integrated Fundamental Market Drivers

Shares Short Prior Month11.75k
Average Daily Volume Last 10 Day3.65k
Average Daily Volume In Three Month11.22k
Date Short Interest27th of February 2009
Fifty Day Average1.0843
Two Hundred Day Average1.0765

Integrated Upcoming Events

Upcoming Quarterly Report11th of November 2021
Next Fiscal Quarter End30th of September 2021

Be your own money manager

Our tools can tell you how much better you can do entering a position in Integrated Biopharma without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Piotroski F Score Now

   

Piotroski F Score

Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Integrated Biopharma using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Check out Risk vs Return Analysis. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Other Tools for Integrated OTC Stock

When running Integrated Biopharma price analysis, check to measure Integrated Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integrated Biopharma is operating at the current time. Most of Integrated Biopharma's value examination focuses on studying past and present price action to predict the probability of Integrated Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Integrated Biopharma's price. Additionally, you may evaluate how the addition of Integrated Biopharma to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go